Helping You Build Wealth With Honest Research
Since 1996. Read On...

The Best Asset Allocation for Your Equity Portfolio

KREBS BIOCHEMICALS Plunges 6%; BSE HEALTHCARE Index Up 0.5%
Tue, 6 Oct 10:55

KREBS BIOCHEMICALS Plunges 6%; BSE HEALTHCARE Index Up 0.5%Image source: phive2015/www.istockphoto.com

KREBS BIOCHEMICALS share price has plunged 6% and is presently trading at Rs 60.0.

Meanwhile, the BSE HEALTHCARE index is at 49,558.3 (up 0.5%).

Among the top losers in the BSE HEALTHCARE index today are J.B.Chemicals (down 3.7%) and METROPOLIS HEALTHCARE (down 2.3%).

LAURUS LABS (up 2.4%) and SUN PHARMA ADV. RES. (up 2.3%) are among the top gainers today.

Over the last one year, KREBS BIOCHEMICALS has moved down from Rs 71.0 to Rs 60.0, registering a loss of Rs 11.0 (down 15.5%).

On the other hand, the BSE HEALTHCARE index has moved up from 43,982.5 to 49,558.3, registering a gain of 12.7% during the last 12 months.

The top gainers among the BSE HEALTHCARE index stocks during this same period were LAURUS LABS (up 133.0%), Divis Laboratories (up 60.2%) and Aurobindo Pharma (up 54.4%).

Discover: Where the opportunities are emerging for the next 3-5 years

What About the Benchmark Indices?

The BSE Sensex is at 72,747.9 (up 0.5%).

The top gainers among the BSE Sensex today are Kotak Bank (up 3.5%) and Indusind Bank (up 2.0%). The most traded stocks in the BSE Sensex are ITC and Kotak Bank.

In the meantime, NSE Nifty is at 22,670.4 (up 0.5%). Trent and Kotak Bank are among the top gainers in NSE NIFTY.

Over the last 12 months, the BSE Sensex has moved down from 81,790.1 to 72,747.9, registering a loss of 9,042.3 points (down 11.1%).

KREBS BIOCHEMICALS Financial Update...

KREBS BIOCHEMICALS net profit grew 53.3% YoY to Rs -25 million for the quarter ended June 2026, compared to a loss of Rs 53 million a year ago. Net sales rose 27.4% to Rs 70 million during the period as against Rs 55 million in April-June 2025.

For the year ended March 2026, KREBS BIOCHEMICALS reported 37.1% increase in net profit to Rs -169 million compared to net loss of Rs 269 million during FY25. Revenue of the company fell 45.2% to Rs 237 million during FY26.

The current Price to earnings ratio of KREBS BIOCHEMICALS, based on rolling 12 month earnings, stands at -9.2.


Equitymaster requests your view! Post a comment on "KREBS BIOCHEMICALS Plunges 6%; BSE HEALTHCARE Index Up 0.5%". Click here!